CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 74 enrolled
Drug / intervention
Tocilizumabdrug
Likely dose
Tocilizumab 4mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01717859
NCT01717859Phase 4Completed
CompareCT.gov

Musculoskeletal Ultrasound in Predicting Early Dose Titration With Tocilizumab

University of California, Los Angeles·interventional·Posted Oct 31, 2012·Updated May 15, 2019

In Brief

A Phase 4 clinical trial evaluating Tocilizumab for Rheumatoid Arthritis. Completed, enrolled 74 participants across 1 site.

Detailed Summary

The purpose of this research study is to determine if a change in inflammation or baseline inflammation seen on the ultrasound is a good indicator of how rheumatoid arthritis patients respond to TCZ 4mg/kg and whether early prediction of dose escalation is possible by utilizing ultrasound inflammatory measures.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesUnited States
CollaboratorsGenentech, Inc.

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedOct 31, 2012
Enrollment StartSep 1, 2014
Primary CompletionApr 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 13.7 years ago

Interventions

Tocilizumabdrug

All subjects will start at 4mg/kg. After 3 months, if DAS28 \> 3.2, dosage will be escalated to 8 mg/kg.